Previous 10 | Next 10 |
ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in addition to one-on-one investor meetings with other members of management, at the upcoming C...
Esperion Therapeutics, Inc. (ESPR) Q4 2021 Earnings Conference Call February 22, 2022 08:00 AM ET Company Participants Ben Church - Investor Relations & Corporate Communications Sheldon Koenig - President & Chief Executive Officer Rick Bartram - Chief Financial Officer Eric Warren - H...
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR) Q4 2021 Earnings Call Feb 22, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics (ESPR) Q4 2021 Earnings Call Transcript
Esperion (ESPR +11.5%) stock rose following its Q4 results which beat analysts' estimates. FY 2021 net product sales grew 208.89% Y/Y to ~$40.05M. U.S. The company said Net Product Revenue of NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) tablets incre...
Esperion Therapeutics press release (NASDAQ:ESPR): Q4 GAAP EPS of -$1.77 beats by $0.52. Revenue of $15.4M (+59.8% Y/Y) beats by $0.92M. As of December 31, 2021, cash, cash equivalents, restricted cash and investment securities available-for-sale totaled $309.3 million compared with $305.0 mi...
– Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022 – – U.S. Net Product Revenue of NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets Grew 12% Seq...
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, before market open. The consensus EPS Estimate is -$2.29 and the consensus Revenue Estimate is $14.48M (+50.2% Y/Y). Over the last 1 year, ESPR has beaten EPS estimates 50% of the time ...
ANN ARBOR, Mich., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, February 22, 2022. Following the release, company management will h...
– Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December – – Fourth-quarter 2021 U.S. Net Product Revenue Estimated Between $12.0 to $12.5 Milli...
ANN ARBOR, Mich., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40 th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...